Cristóbal Bernardo-Castiñeira1, Nuria Valdés2, Marta I Sierra3, Inés Sáenz-de-Santa-María1, Gustavo F Bayón3, Raúl F Perez3,4, Agustín F Fernández3, Mario F Fraga4, Aurora Astudillo5, Rafael Menéndez6, Belén Fernández7, Maribel Del Olmo8, Carlos Suarez1, María-Dolores Chiara1. 1. Head and Neck Oncology Laboratory, Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Institute of Oncology of Asturias (IUOPA), CIBERONC, Oviedo, Spain. 2. Service of Endocrinology and Nutrition, Hospital Universitario Central de Asturias, Oviedo, Spain. 3. Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain. 4. Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo-Principado de Asturias, Oviedo, Spain. 5. Service of Pathology, Hospital Universitario Central de Asturias, Oviedo, Spain. 6. Service of Radiology, Hospital Universitario Central de Asturias, Oviedo, Spain. 7. Service of Nuclear Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain. 8. Service of Endocrinology and Nutrition, Hospital Universitario la Fé, Valencia, Spain.
Abstract
Context: Germline mutations in the succinate dehydrogenase A, B, C, and D genes (collectively, SDHx) predispose to the development of paragangliomas (PGLs) arising at the parasympathetic or sympathetic neuroendocrine systems. SDHx mutations cause absence of tumoral immunostaining for SDHB. However, negative SDHB immunostaining has also been found in a subset of PGLs that lack SDHx mutations. Settings: Here, we report the comprehensive molecular characterization of one such a tumor of parasympathetic origin compared with healthy paraganglia and other PGLs with or without SDHx mutations. Results: Integration of multiplatform data revealed somatic SDHC methylation and loss of the 1q23.3 region containing the SDHC gene. This correlated with decreased SDHC messenger RNA (mRNA) and protein levels. Furthermore, another genetic event found affected the VHL gene, which showed a decreased DNA copy number, associated with low VHL mRNA levels, and an absence of VHL protein detected by immunohistochemistry. In addition, the tumor displayed a pseudohypoxic phenotype consisting in overexpression of the hypoxia-inducible factor (HIF)-1α and miR-210, as well as downregulation of the iron-sulfur cluster assembly enzyme (ISCU) involved in SDHB maturation. This profile resembles that of SDHx- or VHL-mutated PGLs but not of PGLs with decreased VHL copy number, pointing to SDHC rather than VHL as the pathogenic driver. Conclusions: Collectively, these findings demonstrate the potential importance of both the SDHC epigenomic event and the activation of the HIF-1α/miR-210/ISCU axis in the pathogenesis of SDHx wild-type/SDHB-negative PGLs. To our knowledge, this is the first case of a sporadic parasympathetic PGL that carries silencing of SDHC, fulfilling the two-hit Knudson's model for tumorigenesis.
Context: Germline mutations in the succinate dehydrogenase A, B, C, and D genes (collectively, SDHx) predispose to the development of paragangliomas (PGLs) arising at the parasympathetic or sympathetic neuroendocrine systems. SDHx mutations cause absence of tumoral immunostaining for SDHB. However, negative SDHB immunostaining has also been found in a subset of PGLs that lack SDHx mutations. Settings: Here, we report the comprehensive molecular characterization of one such a tumor of parasympathetic origin compared with healthy paraganglia and other PGLs with or without SDHx mutations. Results: Integration of multiplatform data revealed somatic SDHC methylation and loss of the 1q23.3 region containing the SDHC gene. This correlated with decreased SDHC messenger RNA (mRNA) and protein levels. Furthermore, another genetic event found affected the VHL gene, which showed a decreased DNA copy number, associated with low VHL mRNA levels, and an absence of VHL protein detected by immunohistochemistry. In addition, the tumor displayed a pseudohypoxic phenotype consisting in overexpression of the hypoxia-inducible factor (HIF)-1α and miR-210, as well as downregulation of the iron-sulfur cluster assembly enzyme (ISCU) involved in SDHB maturation. This profile resembles that of SDHx- or VHL-mutated PGLs but not of PGLs with decreased VHL copy number, pointing to SDHC rather than VHL as the pathogenic driver. Conclusions: Collectively, these findings demonstrate the potential importance of both the SDHC epigenomic event and the activation of the HIF-1α/miR-210/ISCU axis in the pathogenesis of SDHx wild-type/SDHB-negative PGLs. To our knowledge, this is the first case of a sporadic parasympathetic PGL that carries silencing of SDHC, fulfilling the two-hit Knudson's model for tumorigenesis.
Authors: Jeffrey M Breton; Knarik Arkun; Arthur S Tischler; Adnan S Qamar; Jonathan S Sillman; Carl B Heilman Journal: J Neurosurg Case Lessons Date: 2021-08-02
Authors: Ruth T Casey; Rogier Ten Hoopen; Eguzkine Ochoa; Benjamin G Challis; James Whitworth; Philip S Smith; Jose Ezequiel Martin; Graeme R Clark; Fay Rodger; Mel Maranian; Kieren Allinson; Basetti Madhu; Thomas Roberts; Luis Campos; Joanne Anstee; Soo-Mi Park; Alison Marker; Colin Watts; Venkata R Bulusu; Olivier T Giger; Eamonn R Maher Journal: Sci Rep Date: 2019-07-15 Impact factor: 4.379
Authors: Susan Richter; Bei Qiu; Mirthe Ghering; Carola Kunath; Georgiana Constantinescu; Charlotte Luths; Christina Pamporaki; Nicole Bechmann; Leah Meuter; Aleksandra Kwapiszewska; Timo Deutschbein; Svenja Nölting; Mirko Peitzsch; Mercedes Robledo; Aleksander Prejbisz; Karel Pacak; Volker Gudziol; Henri J L M Timmers; Graeme Eisenhofer Journal: Endocr Relat Cancer Date: 2022-03-21 Impact factor: 5.678